Madrigal Pharmaceuticals Inc MDGL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/10/24 EDT
205.25quote price arrow down-1.67 (-0.81%)
Volume
226,555
52 week range
119.76 - 302.68
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close205.25
  • 52 Week High302.68
  • 52 Week High Date05/23/23
  • 52 Week Low119.76
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap4.369B
  • Shares Out21.28M
  • 10 Day Average Volume0.48M
  • Dividend-
  • Dividend Yield-
  • Beta-0.44
  • YTD % Change-11.29

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close205.25
  • 52 Week High302.68
  • 52 Week High Date05/23/23
  • 52 Week Low119.76
  • 52 Week Low Date10/27/23
  • Market Cap4.369B
  • Shares Out21.28M
  • 10 Day Average Volume0.48M
  • Dividend-
  • Dividend Yield-
  • Beta-0.44
  • YTD % Change-11.29

RATIOS/PROFITABILITY

  • EPS (TTM)-23.08
  • P/E (TTM)-8.89
  • Fwd P/E (NTM)-7.50
  • EBITDA (TTM)-453.626M
  • ROE (TTM)-88.78%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)13.65%

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Madrigal Pharmaceuticals Inc

 

Profile

MORE
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes...
Julian Baker
Independent Chairman of the Board
Bill Sibold
President, Chief Executive Officer, Director
Mardi Dier
Chief Financial Officer, Senior Vice President
Ronald Filippo
Chief Information Officer
Address
200 Barr Harbor Dr Ste 400
West Conshohocken, PA
19428-2978
United States

Top Peers

SYMBOLLASTCHG%CHG
NUVL
Nuvalent Inc
65.48-2.04-3.02%
KRYS
Krystal Biotech Inc
154.76-3.98-2.50%
ALPN
Alpine Immune Sciences Inc
64.94+0.12+0.19%
IOVA
Iovance Biotherapeutics Inc
10.96-2.48-18.48%
CRNX
Crinetics Pharmaceuticals Inc
48.00-1.42-2.87%